Work

Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non‐Diabetic Patient With Cardiac Amyloidosis

Year: 2026

Type: article

Abstract: Dapagliflozin, though beneficial in heart failure, can rarely cause euglycemic ketoacidosis even in non-diabetic patients. Clinicians should maintain a high index of suspicion for metabolic acidosis in patients on SGLT2 inhibitors presenting with unexplained illness, regardless of blood glucose level.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.71818

Authors: Salhamoud Abdelfatah Saleh Hamoud, Ellie Harding

Institution: University Hospitals Plymouth NHS Trust

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820